El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc by (c) Dreyling, Martin et al, 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/200292

The EHA Research Roadmap: Malignant Lymphoid Diseases

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 iming to highlight achievements in the diagnostics and treatment of blood disorders and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1 to 2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cellbased Immune Therapies; and Gene Therapy. © 2022 Wolters Kluwer Health. All rights reserved.

Citació

Citació

DREYLING, Martin, ANDRÉ, Marc, GÖKBUGET, Nicola, TILLY, Hervé, JERKEMAN, Mats, GRIBBEN, John, FERRERI, Andrés, MOREL, Pierre, STILGENBAUER, Stephan, FOX, Christopher, RIBERA, Josep maria, ZWEEGMAN, Sonja, AURER, Igor, BÖDÖR, Csaba, BURKHARDT, Birgit, BUSKE, Christian, CABALLERO, Maria dolores, CAMPO GÜERRI, Elias, CHAPUY, Bjoern, DAVIES, Andrew, LEVAL, Laurence de, DOORDUIJN, Jeanette, FEDERICO, Massimo, GAULARD, Philippe, GAY, Francesca, GHIA, Paolo, GRØNBÆK, Kirsten, GOLDSCHMIDT, Hartmut, KERSTEN, Marie jose, KIESEWETTER, Barbara3, LANDMAN-PARKER, Judith, GOUILL, Steven le, LENZ, Georg, LEPPÄ, Sirpa, LÓPEZ GUILLERMO, Armando, MACINTYRE, Elizabeth, MATEOS MANTEGA, Maria victoria, MOREAU, Philippe, MORENO, Carol, NADEL, Bertrand, OKOSUN, Jessica, OWEN, Roger, POSPISILOVA, Sarka, POTT, Christiane, ROBAK, Tadeusz, SPINA, Michelle, STAMATOPOULOS, Kostas, STARY, Jan, TARTE, Karin, TEDESCHI, Allessandra, THIEBLEMONT, Catherine, TRAPPE, Ralf ulrich, TRÜMPER, Lorenz h., SALLES, Gilles. The EHA Research Roadmap: Malignant Lymphoid Diseases. _Hemasphere_. 2022. Vol.  6, núm. 6, pàgs. e726-NA. [consulta: 3 de gener de 2026]. ISSN: Dreyling M;André M;Gökbuget N;Tilly H;Jerkeman M;Gribben J;Ferreri A;Morel P;Stilgenbauer S;Fox C;Maria Ribera J;Zweegman S;Aurer I;Bödör C;Burkhardt B;Buske C;Dollores Caballero M;Campo E;Chapuy B;Davies A;De Leval L;Doorduijn J;Federico M;Gaulard P;Gay F;Ghia P;Grønbæk K;Goldschmidt H;Kersten MJ;Kiesewetter B;Landman-Parker J;Le Gouill S;Lenz G;Leppä S;López-Guillermo A;MacIntyre E;Mantega MVM;Moreau P;Moreno C;Nadel B. The EHA Research Roadmap: Malignant Lymphoid Diseases. Hemasphere, 2022, 6, 6, e726-NA. [Disponible a: https://hdl.handle.net/2445/200292]

Exportar metadades

JSON - METS

Compartir registre